We then divided the patients into high‐grade (III and IV) and low‐grade (II) gliomas to evaluate the risk of TGIF1 on the prognosis of patients; the expression of TGIF1 has a significant risk for the prognosis of patients with low‐grade glioma was only observed when analyzing the RNA‐seq data from the CGGA and TCGA (HR >1) (Figures S4A–C and S5A–C). This evidence concerns the gene TGIF1 and central nervous system cancer.